Extracorporeal liver support with MARS in liver failure: Has it a role in the treatment of severe alcoholic hepatitis?

Journal of Hepatology

Volumn 38, Issue 1, 2003, Pages 104-106

  Ichai, Philippe ^a   Samuel, Didier ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMINO ACID; BILE ACID; BILIRUBIN; CYTOKINE; MEDIUM CHAIN FATTY ACID; MIDODRINE; TERLIPRESSIN;

ALBUMIN DIALYSIS; ALCOHOL LIVER DISEASE; ANION EXCHANGE; ARTIFICIAL LIVER; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; EDITORIAL; EXTRACORPOREAL CIRCULATION; HEMODIALYSIS; HEMOFILTRATION; HEPATORENAL SYNDROME; HYPERAMMONEMIA; LIVER CIRRHOSIS; LIVER FAILURE; MEAN ARTERIAL PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; SCORING SYSTEM; URINE VOLUME;

HEPATITIS, ALCOHOLIC; HUMANS; LIVER FAILURE; SEVERITY OF ILLNESS INDEX; SORPTION DETOXIFICATION;

EID: 0037232992     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00380-X     Document Type: Editorial

References (20)

1. Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999;23:319-330.
2. Watanabe FD, Mullon CJP, Hewitt WR, Arkadopoulos N, Kakahu E, Egushi S, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 1997;225:484-494.
3. Samuel D, Ichai P, Feray C, Saliba F, Azoulay D, Arulnaden JL, et al. Neurological improvement during bioartificial liver session in patients awaiting liver transplantation. Transplantation 2002;73:257-264.
4. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS results of a prospective randomized controlled clinical trial. Liver Transpl 2000;6:277-286.
5. Heeman U, Treichel U, Loock J, Gerken G, Malago M, Klammt S, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002;36:949-958.
6. Sorkine P, Abraham RB, Szold O, Bidermann P, Kidron A, Merchav H, et al. Role of the molecular adsorbents recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 2001;29:1332-1336.
7. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003; 38:24-31.
8. Schmidt LE, Svendsen LB, Sorensen VR, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 2001;7:709-712.
9. Moreau R, Durand F, Poynard T, Duhamel H, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-930.
10. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-48.
11. Angeli P, Volpin R, Gerunda G, Crainghero R, Roner P, Merenda R, et al. Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-1697.
12. Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416-422.
13. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288-295.
14. Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992;326:507-512.
15. Mathurin P, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36:480-487.
16. Christensen E. Alcoholic hepatitis: glucocorticosteroids or not? J Hepatol 2002;36:547-548.
17. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo controlled trial. Gastroenterology 2000;119:1637-1648.
18. Spahr L, Rubbia-Brandt L, Frossard JL, Giostra E, Rougemont AL, Pugin G, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002;37:448-455.
19. Tome S, Martinez-Rey C, Gonzalez-Quintela A, Gude F, Brage A, Otero E, et al. Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease. J Hepatol 2002;36:793-798.
20. Lucey MR. Is liver transplantation an appropriate treatment for acute alcoholic hepatitis. J Hepatol 2002;36:829-831.